A+ | A | A- | Skip to main content |

800 years stamp

Sensex

Nifty

USDINR

GBPINR

EURINR

BSE
NSE

Tuesday, 21 July 2026 12:05 PM	Asian-Paints2695.65	Hind-Unilever2135.65	ITC281.40	Trent2901.20	Larsen-and-Toubro3830.85	M-and-M3187.50	Reliance-Industries1311.40	Tata-Steel185.45	Titan-Company4675.15	SBI1049.45	Bharat-Electron407.50	Kotak-Mah-Bank385.40	Infosys1077.00	Bajaj-Finance1067.25	Sun-PharmaInds1958.85	HDFC-Bank765.90	TCS2228.20	ICICI-Bank1465.20	Power-Grid-Corpn285.90	Maruti-Suzuki13406.80	Axis-Bank1254.00	HCL-Technologies1232.90	NTPC345.60	Bharti-Airtel1942.80	Tech-Mahindra1587.95	Adani-Ports1839.00	UltraTech-Cem12008.45	Bajaj-Finserv1878.50	Interglobe-Aviat5283.40	Eternal285.10
15 mins delay SENSEX 77,487.59 [-220.93]	4.85 0.18%	-3.40 -0.16%	-1.00 -0.35%	-25.25 -0.86%	-8.75 -0.23%	22.50 0.71%	-11.85 -0.90%	-0.95 -0.51%	32.35 0.70%	-10.45 -0.99%	-0.50 -0.12%	3.35 0.88%	-9.85 -0.91%	3.30 0.31%	2.55 0.13%	-11.75 -1.51%	-21.90 -0.97%	5.05 0.35%	-2.90 -1.00%	-100.65 -0.75%	-2.10 -0.17%	11.90 0.97%	-1.55 -0.45%	2.05 0.11%	11.90 0.76%	-4.15 -0.23%	110.65 0.93%	16.60 0.89%	55.35 1.06%	-1.95 -0.68%

Hot Pursuit

Scrips, which has significant changes during the market hours.

NATCO Pharma rallies after USFDA grants tentative approval for Olaparib tablets

20-Jul-26 09:15Hrs IST

The approved abbreviated new drug application (ANDA) is therapeutically equivalent to the reference listed drug (RLD), Lynparza Tablets, marketed by AstraZeneca Pharmaceuticals, for the indications specified in the approved labelling.

Under the partnership arrangement, NATCO Pharma will manufacture the Olaparib tablets, while Alembic Pharmaceuticals will distribute the product in the United States.

Olaparib, marketed under the brand name Lynparza, is a targeted cancer therapy belonging to the class of PARP inhibitors. It is indicated for the treatment of certain types of ovarian, breast, pancreatic and prostate cancers by preventing cancer cells with specific genetic mutations, such as BRCA or HRR mutations, from repairing damaged DNA.

The company said the Paragraph IV (Para IV) patent litigation related to the product is ongoing. According to industry sales data, Olaparib tablets recorded estimated U.S. sales of approximately USD 1.4 billion for the 12 months ended March 2026.

NATCO Pharma, headquartered in Hyderabad, develops, manufactures and markets generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients (APIs) and crop protection products.

The company reported a 34.11% year-on-year decline in consolidated net profit to Rs 267.9 crore in Q4 FY26, compared with Rs 406.6 crore in the corresponding quarter last year. Revenue from operations declined 39.46% YoY to Rs 739.1 crore during the quarter ended 31 March 2026.

Powered by Capital Market - Live News

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

"Contents which are exclusively for Non-Broking Products/Services, "Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the Member is just a distributor. These are not Exchange traded product and the Member is just acting as distributor. It should also state that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism."

A Muthoot M George Enterprise